Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 12 | 2021 | 307 | 4.640 |
Why?
|
| Alcoholism | 16 | 2021 | 1109 | 3.520 |
Why?
|
| gamma-Aminobutyric Acid | 8 | 2021 | 208 | 3.520 |
Why?
|
| Glutamic Acid | 6 | 2021 | 332 | 2.850 |
Why?
|
| Gyrus Cinguli | 9 | 2021 | 113 | 2.180 |
Why?
|
| Brain | 13 | 2021 | 2176 | 2.000 |
Why?
|
| Alcohol Drinking | 7 | 2019 | 805 | 1.660 |
Why?
|
| Cocaine-Related Disorders | 7 | 2016 | 504 | 1.640 |
Why?
|
| Cues | 11 | 2022 | 654 | 1.520 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 7 | 2021 | 27 | 1.500 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2021 | 346 | 1.360 |
Why?
|
| Impulsive Behavior | 5 | 2019 | 85 | 1.350 |
Why?
|
| Glutamine | 2 | 2019 | 45 | 1.310 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2018 | 782 | 1.150 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2022 | 2223 | 1.090 |
Why?
|
| Taurine | 5 | 2013 | 51 | 1.080 |
Why?
|
| Adult | 40 | 2021 | 21403 | 1.040 |
Why?
|
| Anxiety Disorders | 4 | 2018 | 426 | 1.000 |
Why?
|
| Depressive Disorder | 4 | 2015 | 621 | 0.890 |
Why?
|
| Aspartic Acid | 3 | 2021 | 65 | 0.870 |
Why?
|
| Alcohol Abstinence | 2 | 2020 | 23 | 0.850 |
Why?
|
| Markov Chains | 3 | 2018 | 133 | 0.800 |
Why?
|
| Male | 39 | 2021 | 37321 | 0.790 |
Why?
|
| Female | 38 | 2021 | 38074 | 0.770 |
Why?
|
| Depression | 3 | 2016 | 943 | 0.770 |
Why?
|
| Alcohol Deterrents | 5 | 2013 | 86 | 0.770 |
Why?
|
| Psychometrics | 4 | 2018 | 514 | 0.760 |
Why?
|
| Reward | 2 | 2021 | 201 | 0.750 |
Why?
|
| Young Adult | 18 | 2021 | 5717 | 0.750 |
Why?
|
| Behavior, Addictive | 3 | 2013 | 317 | 0.730 |
Why?
|
| Psychotic Disorders | 2 | 2011 | 157 | 0.680 |
Why?
|
| Delay Discounting | 1 | 2019 | 7 | 0.670 |
Why?
|
| Humans | 50 | 2022 | 68618 | 0.650 |
Why?
|
| Glycine | 1 | 2019 | 89 | 0.650 |
Why?
|
| Middle Aged | 26 | 2021 | 21147 | 0.640 |
Why?
|
| Binge Drinking | 1 | 2019 | 50 | 0.640 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 251 | 0.610 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2021 | 435 | 0.610 |
Why?
|
| Frontal Lobe | 1 | 2019 | 156 | 0.600 |
Why?
|
| Glutathione | 1 | 2019 | 343 | 0.600 |
Why?
|
| Disability Evaluation | 1 | 2018 | 298 | 0.560 |
Why?
|
| Cycloserine | 2 | 2015 | 30 | 0.560 |
Why?
|
| Neurofeedback | 5 | 2016 | 34 | 0.550 |
Why?
|
| Substance-Related Disorders | 4 | 2019 | 1242 | 0.550 |
Why?
|
| Double-Blind Method | 9 | 2021 | 1738 | 0.540 |
Why?
|
| Models, Psychological | 4 | 2016 | 180 | 0.490 |
Why?
|
| Arousal | 2 | 2015 | 168 | 0.490 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7029 | 0.480 |
Why?
|
| Craving | 4 | 2019 | 200 | 0.470 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.440 |
Why?
|
| Personality Inventory | 1 | 2012 | 197 | 0.390 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.380 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.370 |
Why?
|
| Patient Dropouts | 1 | 2011 | 98 | 0.360 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2015 | 257 | 0.350 |
Why?
|
| Self Report | 3 | 2021 | 371 | 0.330 |
Why?
|
| Adolescent | 11 | 2021 | 8912 | 0.320 |
Why?
|
| Tobacco Use Disorder | 4 | 2016 | 432 | 0.320 |
Why?
|
| Cocaine | 4 | 2016 | 555 | 0.310 |
Why?
|
| Depressive Disorder, Major | 2 | 2012 | 439 | 0.310 |
Why?
|
| Motivation | 1 | 2012 | 561 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 468 | 0.300 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 2279 | 0.290 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.290 |
Why?
|
| Quality of Life | 2 | 2012 | 1515 | 0.270 |
Why?
|
| Comorbidity | 4 | 2018 | 1426 | 0.260 |
Why?
|
| Affect | 3 | 2018 | 218 | 0.260 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2018 | 151 | 0.250 |
Why?
|
| Psychomotor Performance | 2 | 2019 | 213 | 0.250 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 951 | 0.240 |
Why?
|
| Datasets as Topic | 3 | 2019 | 53 | 0.240 |
Why?
|
| Photic Stimulation | 3 | 2013 | 229 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2077 | 0.220 |
Why?
|
| Factor Analysis, Statistical | 4 | 2016 | 201 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 1054 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2021 | 1342 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1085 | 0.200 |
Why?
|
| Altitude | 1 | 2021 | 17 | 0.190 |
Why?
|
| Checklist | 1 | 2022 | 76 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 329 | 0.190 |
Why?
|
| Naltrexone | 2 | 2013 | 195 | 0.190 |
Why?
|
| Punishment | 1 | 2021 | 25 | 0.190 |
Why?
|
| Risk-Taking | 2 | 2013 | 210 | 0.180 |
Why?
|
| Brain Mapping | 2 | 2014 | 532 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2013 | 1034 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 104 | 0.170 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 128 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 78 | 0.170 |
Why?
|
| Commerce | 1 | 2020 | 80 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 51 | 0.170 |
Why?
|
| Regression Analysis | 3 | 2011 | 737 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 1465 | 0.160 |
Why?
|
| 4-Aminobutyrate Transaminase | 1 | 2018 | 4 | 0.160 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2800 | 0.160 |
Why?
|
| Proline | 1 | 2018 | 52 | 0.160 |
Why?
|
| Executive Function | 1 | 2019 | 106 | 0.160 |
Why?
|
| Databases, Factual | 1 | 2021 | 622 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 4655 | 0.150 |
Why?
|
| Functional Neuroimaging | 3 | 2013 | 82 | 0.150 |
Why?
|
| Smoking | 3 | 2016 | 1452 | 0.150 |
Why?
|
| Models, Statistical | 2 | 2013 | 448 | 0.150 |
Why?
|
| Antioxidants | 1 | 2019 | 304 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2020 | 3705 | 0.140 |
Why?
|
| Aged | 5 | 2020 | 14862 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 206 | 0.140 |
Why?
|
| Prefrontal Cortex | 2 | 2013 | 640 | 0.140 |
Why?
|
| Acetylcysteine | 1 | 2020 | 296 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.140 |
Why?
|
| Primary Health Care | 2 | 2012 | 703 | 0.130 |
Why?
|
| Yohimbine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 89 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3259 | 0.130 |
Why?
|
| Interview, Psychological | 3 | 2012 | 113 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 659 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 955 | 0.120 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.120 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 108 | 0.120 |
Why?
|
| Oxygen | 2 | 2013 | 386 | 0.120 |
Why?
|
| Attention | 1 | 2016 | 225 | 0.120 |
Why?
|
| Linear Models | 2 | 2012 | 521 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.110 |
Why?
|
| Temperance | 1 | 2013 | 41 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 627 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2013 | 85 | 0.110 |
Why?
|
| Implosive Therapy | 1 | 2015 | 171 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 689 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 237 | 0.100 |
Why?
|
| Age of Onset | 1 | 2012 | 188 | 0.100 |
Why?
|
| Narcotic Antagonists | 1 | 2013 | 184 | 0.100 |
Why?
|
| Somatoform Disorders | 1 | 2011 | 35 | 0.100 |
Why?
|
| Personality | 1 | 2011 | 66 | 0.090 |
Why?
|
| Aggression | 1 | 2011 | 98 | 0.090 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 649 | 0.090 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 340 | 0.090 |
Why?
|
| Ethanol | 1 | 2016 | 893 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2012 | 297 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 536 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 1506 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2011 | 291 | 0.080 |
Why?
|
| Veterans | 2 | 2020 | 904 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 221 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 792 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2011 | 402 | 0.080 |
Why?
|
| United States | 2 | 2018 | 7367 | 0.080 |
Why?
|
| Health Surveys | 1 | 2008 | 489 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2011 | 824 | 0.060 |
Why?
|
| Risk Factors | 1 | 2012 | 5731 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 62 | 0.050 |
Why?
|
| Utah | 1 | 2021 | 27 | 0.050 |
Why?
|
| Creatine | 1 | 2021 | 30 | 0.050 |
Why?
|
| Smoking Prevention | 2 | 2013 | 259 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4848 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2005 | 659 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 7277 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 579 | 0.040 |
Why?
|
| Water | 1 | 2019 | 230 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 729 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 119 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 260 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 386 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1864 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 114 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 216 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2016 | 295 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2015 | 240 | 0.030 |
Why?
|
| Volition | 1 | 2012 | 16 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 85 | 0.030 |
Why?
|
| Imagination | 1 | 2012 | 38 | 0.030 |
Why?
|
| Body Temperature | 1 | 2012 | 116 | 0.020 |
Why?
|
| South America | 1 | 2011 | 8 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 447 | 0.020 |
Why?
|
| India | 1 | 2011 | 41 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 392 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2011 | 60 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 196 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 291 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 384 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1753 | 0.020 |
Why?
|
| Child | 1 | 2016 | 6405 | 0.020 |
Why?
|